PHA-543613 is a potent selective a7 nAChR agonist. Nicotinic acetylcholine receptors are ligand-gated ion channels activated by nicotine, expressed in multiple tissues, with high functional expression in brain. The homomeric subtype a7 is a potential therapeutic target for cognitive deficits in schizophrenia and Alzheimer?s disease. PHA-543613 is active in both in vitro (binding, calcium flux, patch-clamp) and in vivo (auditory gating, novel object recognition) assays.
Form:
Tan Solid
Melting Point:
>300 degrees C
Solubility:
DMSO, Methanol
Pfizer Compound